Elevated white cell count in acute coronary syndromes: Relationship to variants in inflammatory and thrombotic genes

BMC Medical Genetics

Volumn 5, Issue , 2004, Pages

  Byrne, Connie E ^a   Fitzgerald, Anthony ^a   Cannon, Christopher P ^b   Fitzgerald, Desmond J ^a   Shields, Denis C ^a  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; FIBRINOGEN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 6; ORBOFIBAN; XEMILOFIBAN; BIOLOGICAL MARKER; IL1RN PROTEIN, HUMAN; SIALOGLYCOPROTEIN;

ANTICOAGULANT THERAPY; ARTICLE; CAUCASIAN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY THROMBOSIS; CORRELATION ANALYSIS; DISEASE EXACERBATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HEART MUSCLE ISCHEMIA; HOMOZYGOSITY; HUMAN; HUMAN CELL; INFLAMMATION; INTRON; LEUKOCYTOSIS; MAJOR CLINICAL STUDY; RECURRENCE RISK; UNSTABLE ANGINA PECTORIS; ACUTE DISEASE; BLOOD; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; GENETICS; HEART INFARCTION; IMMUNOLOGY; LEUKOCYTE COUNT; RECURRENT DISEASE; RISK FACTOR; SYNDROME;

ACUTE DISEASE; ANGINA, UNSTABLE; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CLINICAL TRIALS AS TOPIC; CORONARY THROMBOSIS; FIBRINOGEN; GENETIC VARIATION; GENOTYPE; HUMANS; INFLAMMATION; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-6; LEUKOCYTE COUNT; MYOCARDIAL INFARCTION; POLYMORPHISM, GENETIC; RECURRENCE; RISK FACTORS; SIALOGLYCOPROTEINS; SYNDROME;

EID: 26444441021     PISSN: 14712350     EISSN: 14712350     Source Type: Journal    
DOI: 10.1186/1471-2350-5-13     Document Type: Article

References (38)

1. Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V: Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 2000, 148:209-214.
2. Lowe GD, Machado SG, Krol WF, Barton BA, Forbes CD: White blood cell count and haematocrit as predictors of coronary recurrence after myocardial infarction. Thromb Haemost 1985, 54:700-703.
3. Burr ML, Holliday RM, Fehily AM, Whitehead PJ: Haematological prognostic indices after myocardial infarction: evidence from the diet and reinfarction trial (DART). Eur Heart J 1992, 13:166-170.
4. Cannon CP, McCabe CH, Wilcox RG, Bentley JH, Braunwald E: Association of white blood cell count with increased mortality in acute myocardial infarction and unstable angina pectoris. OPUS-TIMI 16 Investigators. Am J Cardiol 2001, 87:636-9, A10.
5. Barron HV, Cannon CP, Murphy SA, Braunwald E, Gibson CM: Association between white blood cell count, epicardial blood flow, myocardial perfusion, and clinical outcomes in the setting of acute myocardial infarction: a thrombolysis in myocardial infarction 10 substudy. Circulation 2000, 102:2329-2334.
6. Volpato S, Guralnik JM, Ferrucci L, Balfour J, Chaves P, Fried LP, Harris TB: Cardiovascular disease, interleukin-6, and risk of mortality in older women: the women's health and aging study. Circulation 2001, 103:947-953.
7. Rosalki SB: C-reactive protein. Int J Clin Pract 2001, 55:269-270.
8. Berk BC, Weintraub WS, Alexander RW: Elevation of C-reactive protein in "active" coronary artery disease. Am J Cardiol 1990, 65:168-172.
9. Liuzzo G, Biasucci LM, Rebuzzi AG, Gallimore JR, Caligiuri G, Lanza GA, Quaranta G, Monaco C, Pepys MB, Maseri A: Plasma protein acute-phase response in unstable angina is not induced by ischemic injury. Circulation 1996, 94:2373-2380.
10. Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, Maseri A: The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 1994, 331:417-424.
11. Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB: Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 1997, 349:462-466.
12. Zebrack JS, Anderson JL, Maycock CA, Horne BD, Bair TL, Muhlestein JB: Usefulness of high-sensitivity C-reactive protein in predicting long-term risk of death or acute myocardial infarction in patients with unstable or stable angina pectoris or acute myocardial infarction. Am J Cardiol 2002, 89:145-149.
13. Toss H, Gnarpe J, Gnarpe H, Siegbahn A, Lindahl B, Wallentin L: Increased fibrinogen levels are associated with persistent Chlamydia pneumoniae infection in unstable coronary artery disease. Eur Heart J 1998, 19:570-577.
14. Levenson J, Giral P, Razavian M, Gariepy J, Simon A: Fibrinogen and silent atherosclerosis in subjects with cardiovascular risk factors. Arterioscler Thromb Vasc Biol 1995, 15:1263-1268.
15. Tracy RP, Bovill EG, Yanez D, Psaty BM, Fried LP, Heiss G, Lee M, Polak JF, Savage PJ: Fibrinogen and factor VIII, but not factor VII, are associated with measures of subclinical cardiovascular disease in the elderly. Results from The Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 1995, 15:1269-1279.
16. Keightley AM, Lam YM, Brady JN, Cameron CL, Lillicrap D: Variation at the von Willebrand factor (vWF) gene locus is associated with plasma vWF:Ag levels: identification of three novel single nucleotide polymorphisms in the vWF gene promoter. Blood 1999, 93:4277-4283.
17. Yarnell JW, Baker IA, Sweetnam PM, Bainton D, O'Brien JR, Whitehead PJ, Elwood PC: Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease. The Caerphilly and Speedwell collaborative heart disease studies. Circulation 1991, 83:836-844.
18. Panichi V, Migliori M, De Pietro S, Taccola D, Andreini B, Metelli MR, Giovannini L, Palla R: The link of biocompatibility to cytokine production. Kidney Int Suppl 2000, 76:S96-103.
19. Benderly M, Graff E, Reicher-Reiss H, Behar S, Brunner D, Goldbourt U: Fibrinogen is a predictor of mortality in coronary heart disease patients. The Bezafibrate Infarction Prevention (BIP) Study Group. Arterioscler Thromb Vasc Biol 1996, 16:351-356.
20. Huber SA, Sakkinen P, Conze D, Hardin N, Tracy R: Interleukin-6 exacerbates early atherosclerosis in mice. Arterioscler Thromb Vasc Biol 1999, 19:2364-2367.
21. El-Omar EM, Carrington M, Chow WH, McColl KE, Bream JH, Young HA, Herrera J, Lissowska J, Yuan CC, Rothman N, Lanyon G, Martin M, Fraumeni J. F., Jr., Rabkin CS: Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000, 404:398-402.
22. Tarlow JK, Blakemore AI, Lennard A, Solari R, Hughes HN, Steinkasserer A, Duff GW: Polymorphism in human 1L-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat. Hum Genet 1993, 91:403-404.
23. Cork MJ, Tarlow JK, Clay FE, Crane A, Blakemore AI, McDonagh AJ, Messenger AG, Duff GW: An allele of the interleukin-1 receptor antagonist as a genetic severity factor in alopecia areata. J Invest Dermatol 1995, 104:15S-16S.
24. Blakemore AI, Cox A, Gonzalez AM, Maskil JK, Hughes ME, Wilson RM, Ward JD, Duff GW: Interleukin-1 receptor antagonist allele (1L1RN*2) associated with nephropathy in diabetes mellitus. Hum Genet 1996, 97:369-374.
25. Witkin SS, Gerber S, Ledger WJ: Influence of interleukin-1 receptor antagonist gene polymorphism on disease. Clin Infect Dis 2002, 34:204-209.
26. Shibata M, Endo S, Inada K, Kuriki S, Harada M, Takino T, Sato N, Arakawa N, Suzuki T, Aoki H, Hiramori K: Elevated plasma levels of interleukin-1 receptor antagonist and interleukin-10 in patients with acute myocardial infarction. J Interferon Cytokine Res 1997, 17:145-150.
27. Francis SE, Camp NJ, Dewberry RM, Gunn J, Syrris P, Carter ND, Jeffery S, Kaski JC, Cumberland DC, Duff GW, Crossman DC: Interleukin-1 receptor antagonist gene polymorphism and coronary artery disease. Circulation 1999, 99:861-866.
28. Zee RY, Lunze K, Lindpaintner K, Ridker PM: A prospective evaluation of the interleukin-1 receptor antagonist intron 2 gene polymorphism and the risk of myocardial infarction. Thromb Haemost 2001, 86:1141-1143.
29. Burzotta F, Iacoviello L, Di Castelnuovo A, Glieca F, Luciani N, Zamparelli R, Schiavello R, Donati MB, Maseri A, Possati G, Andreotti F: Relation of the -174 G/C polymorphism of interleukin-6 to interleukin-6 plasma levels and to length of hospitalization after surgical coronary revascularization. Am J Cardiol 2001, 88:1125-1128.
30. Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S, Woo P: The effect of novel polymorphisms in the interleukin-6 (1L-6) gene on 1L-6 transcription and plasma 1L-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998, 102:1369-1376.
31. Foster CB, Lehrnbecher T, Samuels S, Stein S, Mol F, Metcalf JA, Wyvill K, Steinberg SM, Kovacs J, Blauvelt A, Yarchoan R, Chanock SJ: An 1L6 promoter polymorphism is associated with a lifetime risk of development of Kaposi sarcoma in men infected with human immunodeficiency virus. Blood 2000, 96:2562-2567.
32. Rauramaa R, Vaisanen SB, Luong LA, Schmidt-Trucksass A, Penttila IM, Bouchard C, Toyry J, Humphries SE: Stromelysin-1 and interleukin-6 gene promoter polymorphisms are determinants of asymptomatic carotid artery atherosclerosis. Arterioscler Thromb Vasc Biol 2000, 20:2657-2662.
33. Cannon CP, McCabe CH, Wilcox RG, Langer A, Caspi A, Berink P, Lopez-Sendon J, Toman J, Charlesworth A, Anders RJ, Alexander JC, Skene A, Braunwald E: Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. Circulation 2000, 102:149-156.
34. O'Neill WW, Serruys P, Knudtson M, van Es GA, Timmis GC, van der Zwaan C, Kleiman J, Gong J, Roecker EB, Dreiling R, Alexander J, Anders R: Long-term treatment with a platelet glycoproteinreceptor antagonist after percutaneous coronary revascularization. EXCITE Trial Investigators. Evaluation of Oral Xemilofiban in Controlling Thrombotic Events. N Engl J Med 2000, 342:1316-1324.
35. Shields DC, Fitzgerald AP, O'Neill PA, Muckian C, Kenny D, Moran B, Cannon CP, Byrne CE, Fitzgerald DJ: The contribution of genetic factors to thrombotic and bleeding outcomes in coronary patients randomised to IIb/IIIa antagonists. Pharmacogenomics J 2002, 2:182-190.
36. Zee RY, Ridker PM: Polymorphism in the human C-reactive protein (CRP) gene, plasma concentrations of CRP, and the risk of future arterial thrombosis. Atherosclerosis 2002, 162:217-219.
37. Fernandez-Real JM, Vendrell J, Richart C, Gutierrez C, Ricart W: Platelet count and Interleukin 6 Gene polymorphism in healthy subjects. BMC Med Genet 2001, 2:6-9.
38. Lindemann S, Tolley ND, Dixon DA, McIntyre TM, Prescott SM, Zimmerman GA, Weyrich AS: Activated platelets mediate inflammatory signaling by regulated interleukin 1beta synthesis. J Cell Biol 2001, 154:485-490.